Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations - Müller, Martin C.; Cortes, Jorge E.; Kim, Dong-Wook; Druker, Brian J.; Erben, Philipp; Pasquini, Ricardo; Branford, Susan; Hughes, Timothy P.; Radich, Jerald P.; Ploughman, Lynn; Mukhopadhyay, Jaydip; Hochhaus, Andreas (Blood, 2009)
Keywords: Adolescent; Adult; Aged; Aged, 80 and over; Biological and medical sciences; Chromosome aberrations; Clinical Trials and Observations; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dasatinib; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl - genetics; Hematologic and hematopoietic diseases; Humans; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical genetics; Medical sciences; Middle Aged; Mutation; Protein Kinase Inhibitors - therapeutic use; Pyrimidines - therapeutic use; Randomized Controlled Trials as Topic; Thiazoles - therapeutic use; Treatment Outcome; Young Adult; Chromosomal aberration; Antineoplastic agent; Dasatinib; Hematology; Enzyme; Tyrosine kinase inhibitor; Transferases; Non-specific serine/threonine protein kinase; Chronic myelogenous leukemia; Malignant hemopathy; Philadelphia chromosome; Myeloproliferative syndrome; Abnormal chromosome C9; Treatment; bcr gene; C-Onc gene; Abnormal chromosome G22; Abnormal chromosome; Genetics; Multikinase inhibitor; Mutation; Hybrid gene; Cancer; Chromosome translocation